Drug for Parkinson's not likely to cause melanoma

People with the movement disorder Parkinson’s disease have a much higher risk of the skin cancer melanoma, and vice versa, a Mayo Clinic study finds. Yet the results of the study argue against the Parkinson's drug levodopa as the cause.

The study found that patients with Parkinson’s were roughly four times...
The study found that patients with Parkinson’s were roughly four times likelier to have had a history of melanoma than those without Parkinson’s.
Source: Pixabay

Overall, patients with Parkinson’s were roughly four times likelier to have had a history of melanoma than those without Parkinson’s, and people with melanoma had a fourfold higher risk of developing Parkinson’s, the research found. Medical experts have speculated about the relationship between Parkinson’s and melanoma for decades, with varying conclusions, the Mayo researchers note. Several studies have suggested levodopa, a drug for Parkinson’s, may be implicated in malignant melanoma, but the study did not confirm this.

Common abnormalities could cause relation

The Mayo study used the Rochester Epidemiology Project medical records database to identify all neurologist-confirmed Parkinson’s cases from January 1976 through December 2013 among Olmsted County, Minn., residents. The study examined the prevalence of melanoma in those 974 patients compared with 2,922 residents without Parkinson’s. They also identified 1,544 cases of melanoma over that period and determined the 35-year risk of Parkinson’s in those patients compared with the risk in the same number of people without melanoma. The results support an association between Parkinson’s disease and melanoma, but argue against levodopa as the cause, the researchers conclude. It is likelier that common environmental, genetic or immune system abnormalities underlie both conditions in patients who have both, but more research is needed to confirm that and refine screening recommendations, they say.

In the meantime, patients with one of the two diseases should be monitored for the other to help achieve early diagnosis and treatment, and they should be educated about the risk of developing the other illness, the researchers say. The study’s senior author is Jose Pulido, M.D., an ophthalmologist at Mayo Clinic in Rochester, Minnesota, who treats eye melanoma.
 

Source: Mayo Clinic

09.07.2017

Related articles

Photo

News • Saliva test device

Breast cancer screening: Biosensor could offer alternative to diagnostic imaging

A newly-developed biosensor could be an alterative to MRI and mammography for breast cancer screening. The handheld device uses saliva on test strips to determine whether cancer is present.

Photo

News • Detection of lumps

New robot could help diagnose breast cancer early

A team at the University of Bristol has developed a robot manipulator that could carry out clinical breast examinations. The developers hope the device will revolutionise breast health monitoring.

Photo

News • Oncology early detection tool

Blood test for 50+ types of cancer promising for screening

Final results from a study of a blood test that can detect more than 50 types of cancer have shown that it is accurate enough to be rolled out as a multi-cancer screening test among people at higher…

Related products

Subscribe to Newsletter